This is a multicenter, prospective observational cohort study, in which patients with chronic airway diseases including chronic obstructive pulmonary disease(COPD), asthma, asthma-COPD overlap syndrome (ACOS) will be recruited.
Postbronchodilator FEV1/FVC < 0.7 AND chronic respiratory symptom
Never smoker or <5PY of smoking history AND Recurrent episodes of asthma symptoms (wheezing, dyspnea, chest tightness, cough) AND (either Positive BDR OR positive metacholine/mannitol/exercise provocation test)
COPD AND Asthma (regardless of smoking status)
COPD Asthma ACOS Bronchiectasis TB-destroyed lung Other chronic airway diseases
Cohort
Prospective
Not listed
Death (time to death)
death from any cause, death from COPD-specific cause, death from CVD, malignancy
post-bronchodilator FEV1 change rates
Time to 1st exacerbation (definition of exacerbation is described below)
Definition of exacerbation: Airway disease symptom aggravation requiring either (1) Use of antibiotics or steroid, or (2) visiting ER or hospitalization
Annual rate of exacerbation (definition of exacerbation is described below)
Definition of exacerbation: Airway disease symptom aggravation requiring either (1) Use of antibiotics or steroid, or (2) visiting ER or hospitalization
Click on the lead sponsor to view all of their trials.
